breast center
Recently Published Documents


TOTAL DOCUMENTS

107
(FIVE YEARS 25)

H-INDEX

13
(FIVE YEARS 2)

Author(s):  
Vidya R Pai ◽  
Murray Rebner

Abstract Anxiety has been portrayed by the media and some organizations and societies as one of the harms of mammography. However, one experiences anxiety in multiple different medical tests that are undertaken, including screening examinations; it is not unique to mammography. Some may argue that because this anxiety is transient, the so-called harm is potentially overstated, but for some women the anxiety is significant. Anxiety can increase or decrease the likelihood of obtaining a screening mammogram. There are multiple ways that anxiety associated with screening mammography can be diminished, including before, during, and after the examination. These include simple measures such as patient education, improved communication, being aware of the patient’s potential discomfort and addressing it, validating the patient’s anxiety as well as providing the patient with positive factual data that can easily be implemented in every breast center. More complex interventions include altering the breast center environment with multisensory stimulation, reorganization of patient flow to minimize wait times, and relaxation techniques including complementary and alternative medicine. In this article we will review the literature on measures that can be taken to minimize anxiety that would maximize the likelihood of a woman obtaining an annual screening mammogram.


The Breast ◽  
2021 ◽  
Vol 56 ◽  
pp. S77-S78
Author(s):  
D. Varvaras ◽  
M.G. Lo Schiavo ◽  
V. De Felice ◽  
S. Tardioli ◽  
G. Papadopoulos ◽  
...  

2021 ◽  
Vol 18 (01) ◽  
pp. 31-32
Author(s):  
Elisabeth Artemis Kappos ◽  
Walter Paul Weber ◽  
Christian Kurzeder ◽  
Martin Haug

Author(s):  
Kaitlyn Kennard ◽  
Austin D. Williams ◽  
Lindsay G. Goldblatt ◽  
Meghan E. Buckley ◽  
Laura Bruce ◽  
...  

Breast Care ◽  
2021 ◽  
Vol 16 (2) ◽  
pp. 129-134
Author(s):  
Anna Hester ◽  
Franziska Henze ◽  
Christiane Travi ◽  
Nadia Harbeck ◽  
Rachel Wuerstlein

<b><i>Introduction:</i></b> The phosphatidylinositol-3-kinase (PI3K) inhibitor alpelisib is the only approved agent for treating ­<i>PIK3CA</i>-mutated, hormone receptor-positive (HR+) human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC). Trials have reported hyperglycemia, diarrhea, and rash as the main grade 3 side effects. <b><i>Methods:</i></b> In a managed access program (ClinicalTrials.gov ID: NCT03706573; start: 06/2019), 8 HR+ HER2– ABC patients with a median 4.5 prior therapy lines were treated with alpelisib at the Breast Center of the Ludwig-Maximilian University (LMU) Hospital, Munich, based on the results of a new-generation sequencing (NGS) panel and <i>PIK3CA</i> mutation analysis by the Molecular Tumor Board of the Comprehensive Cancer Center, Munich. <b><i>Results:</i></b> Median therapy duration was 3.42 months for patients who discontinued and 3.95 months for those still on alpelisib (4 pts). Five had hyperglycemia (1 with grade 3) with fasting glucose levels of up to 450 mg/dL that required hospitalization and insulin therapy. Two experienced rash (grades 1 and 3) and 2 reported grade 3 diarrhea. Supportive therapy as well as interruption and/or dose reduction were necessary to control treatment-associated side effects. <b><i>Conclusion:</i></b> Patient education and a well-trained, interdisciplinary team including diabetologists, from the initiation of alpelisib treatment onwards, are essential to safely treat ABC patients with this new drug and to maintain their quality of life and ensure their survival.


2020 ◽  
Vol 49 (6) ◽  
pp. 412-416 ◽  
Author(s):  
Kellie Chiu ◽  
Nikki Tirada ◽  
Prasann Vachhani ◽  
Luke Robinson ◽  
Gauri Khorjekar

Sign in / Sign up

Export Citation Format

Share Document